Juvenile idiopathic arthritis: improved outcome requires improved access to care.

摘要

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children worldwide [1] with a range of clinical presentations and outcomes [2]. Improving the outcome for children with JIA is an important goal in paediatric rheumatology, and current management of severe JIA involves increasingly aggressive immunosuppression [2, 3], although often based on extrapolation of clinical experience in adult RA. The advent of immunomodulatory treatments have resulted in an improved quality of life for many children and the need for improved clinical trials in JIA has been highlighted [4].